Cancer Patients Treated With Sunitinib or Sorafenib Have Sufficient Antibody and Cellular Immune Responses to Warrant Influenza Vaccination
Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-11-0253
Full Text
Open PDFAbstract
Available in full text
Date
June 28, 2011
Authors
Publisher
American Association for Cancer Research (AACR)